Despite all the big deals announced in December, the fourth quarter of 2017 wasn’t one for the record books. Merger and acquisition activity was busy, but compared with the previous quarter and the same period in 2016, the pace wasn’t frenetic. Our preliminary data shows 357 transactions were announced in Q4:17, down a slight 4% […]
Investors have flocked to the “Other Services” sector this year, as its ancillary nature keeps the companies that comprise it largely outside the purview of reimbursement regulations and other stroke-of-the-pen sectors.
Acquisitions of dermatology practices are surging in 2017. Through mid-November, we’ve counted 37 transactions for these physician practices, up nearly 46% compared with all of 2016 (26 announced transactions). Epiphany Dermatology, a portfolio company of CI Capital Partners, has been the busiest acquirer this year, with eight transactions concentrated in Arizona, New Mexico, Oklahoma and […]
“Sluggish” is the best word to describe deal activity in the Pharmaceutical sector this year. Mergers and acquisitions have dropped every quarter since the third quarter of 2016. In Q3:17, this dearth of deals may have finally bottomed out.
Physician medical groups are still hot properties, of course. But the rate of consolidation within the industry accelerated rapidly in the past two years, and it was inevitable the pace would slacken at some point.
Merger and acquisition activity in the eHealth sector decreased in the third quarter, down 5% compared with the previous quarter, to 42 deals. However, the quarter’s results were 45% higher than the same period a year earlier. The third quarter’s total represents a 26% share of the 164 deals announced in the previous 12 months. […]
The Home Health & Hospice sector has been buffeted by headwinds in 2017. Besides the ongoing labor shortage and federal fraud investigations, the President’s recently signed executive orders affecting cost-sharing reductions for families and individuals earning less than 400% of the federal poverty level could curtail use of home health agencies.
Biotechnology deal activity slid further in the third quarter, down 22% to 42 transactions, compared with the second quarter’s 54 transactions. The total represents 19% of the 217 deals announced in the previous 12 months.
Behavioral health care transactions regained some of the strength they lost in the second quarter of 2017. Deal volume in the sector rose 63% in the third quarter, and was up 86% compared with the third quarter of 2016.
Our Stat of the Week is -57%, which is how far spending on healthcare mergers and acquisitions fell in the third quarter of 2017.